Omeros Corporation Reports Third Quarter 2024 Financial Results
Omeros (OMER) reported Q3 2024 financial results with a net loss of $32.2 million ($0.56 per share), compared to $37.8 million ($0.60 per share) in Q3 2023. The company held $123.2 million in cash and short-term investments, down $48.7 million from December 2023. OMIDRIA royalties were $9.3 million on $31.0 million U.S. net sales. Key developments include FDA discussions for narsoplimab BLA resubmission in TA-TMA, planned European MAA submission in H1 2025, and advancement of zaltenibart's Phase 2 program in PNH with Phase 3 enrollment expected in early 2025.
Omeros (OMER) ha riportato i risultati finanziari del terzo trimestre del 2024 con una perdita netta di $32,2 milioni ($0,56 per azione), rispetto ai $37,8 milioni ($0,60 per azione) nel terzo trimestre del 2023. L'azienda deteneva $123,2 milioni in cassa e investimenti a breve termine, in calo di $48,7 milioni rispetto a dicembre 2023. Le royalties di OMIDRIA sono state di $9,3 milioni su $31,0 milioni di vendite nette negli Stati Uniti. Sviluppi chiave includono discussioni con la FDA per la reiscrizione del BLA di narsoplimab in TA-TMA, la pianificazione della sottomissione della MAA europea nel primo semestre del 2025 e il progresso del programma di Fase 2 di zaltenibart in PNH, con un'arruolamento della Fase 3 previsto per inizio 2025.
Omeros (OMER) informó resultados financieros del tercer trimestre de 2024 con una pérdida neta de $32.2 millones ($0.56 por acción), en comparación con $37.8 millones ($0.60 por acción) en el tercer trimestre de 2023. La compañía tenía $123.2 millones en efectivo e inversiones a corto plazo, una disminución de $48.7 millones desde diciembre de 2023. Las regalías de OMIDRIA fueron de $9.3 millones sobre ventas netas de $31.0 millones en EE. UU. Los desarrollos clave incluyen discusiones con la FDA para la reinscripción del BLA de narsoplimab en TA-TMA, la presentación planificada de la MAA europea en el primer semestre de 2025 y el avance del programa de Fase 2 de zaltenibart en PNH, con un reclutamiento de Fase 3 esperado a inicios de 2025.
오메로스 (OMER)는 2024년 3분기 재무 결과로 3천220만 달러 ($0.56 주당 손실)의 순손실을 보고했으며, 이는 2023년 3분기의 3천780만 달러 ($0.60 주당 손실)와 비교됩니다. 이 회사는 현금 및 단기 투자로 1억2320만 달러를 보유하고 있으며, 이는 2023년 12월 대비 4천870만 달러 감소한 수치입니다. OMIDRIA 로열티는 미주에서 3천100만 달러의 순판매에 대해 930만 달러였습니다. 주요 개발 사항으로는 TA-TMA에서 narsoplimab의 BLA 재제출을 위한 FDA와의 논의, 2025년 상반기 유럽 MAA 제출 계획, PNH에서 zaltenibart의 2상 프로그램 발전과 2025년 초에 3상 연구 계획이 포함됩니다.
Omeros (OMER) a annoncé des résultats financiers pour le troisième trimestre 2024 avec une perte nette de 32,2 millions de dollars (0,56 $ par action), par rapport à 37,8 millions de dollars (0,60 $ par action) au troisième trimestre 2023. La société détenait 123,2 millions de dollars en liquidités et en investissements à court terme, en baisse de 48,7 millions de dollars par rapport à décembre 2023. Les redevances d'OMIDRIA se sont élevées à 9,3 millions de dollars sur des ventes nettes américaines de 31 millions de dollars. Les développements clés incluent des discussions avec la FDA concernant la nouvelle soumission du BLA de narsoplimab dans la TA-TMA, la soumission prévue de la MAA européenne au premier semestre 2025 et l'avancement du programme de phase 2 de zaltenibart dans le PNH, avec une inscription en phase 3 prévue début 2025.
Omeros (OMER) berichtete über die finanziellen Ergebnisse für das 3. Quartal 2024 mit einem Nettoverlust von 32,2 Millionen Dollar (0,56 Dollar pro Aktie), verglichen mit 37,8 Millionen Dollar (0,60 Dollar pro Aktie) im 3. Quartal 2023. Das Unternehmen hielt 123,2 Millionen Dollar in Bargeld und kurzfristigen Investitionen, was einem Rückgang von 48,7 Millionen Dollar seit Dezember 2023 entspricht. Die Lizenzgebühren von OMIDRIA betrugen 9,3 Millionen Dollar bei 31 Millionen Dollar Nettoumsatz in den USA. Zu den wichtigen Entwicklungen gehören Gespräche mit der FDA zur erneuten Einreichung des BLA von narsoplimab in TA-TMA, die geplante Einreichung der europäischen MAA im ersten Halbjahr 2025 und der Fortschritt des Phase-2-Programms von zaltenibart in PNH, wobei die Rekrutierung für Phase 3 Anfang 2025 erwartet wird.
- Operating expenses decreased to $35.4M from $48.2M YoY
- Interest expense reduced to $4.1M from $7.9M YoY
- Earned $9.3M in OMIDRIA royalties
- Net loss of $32.2M in Q3 2024
- Cash position decreased by $48.7M since December 2023
- Nine-month net loss increased to $125.5M from $108.8M YoY
- OMIDRIA royalties declined from $10.0M to $9.3M YoY
Insights
The Q3 results reveal concerning financial metrics. Net loss of
OMIDRIA royalties declined
The regulatory pathway for narsoplimab in TA-TMA shows progress with FDA feedback to minor statistical analysis revisions. Zaltenibart's development is advancing rapidly, with Phase 3 trials in PNH set for early 2025 following positive regulatory discussions. The company's pipeline diversification includes promising developments in:
- OMS1029 completing Phase 1 with quarterly dosing potential
- OMS527 advancing toward clinical trials for cocaine use disorder
- Emerging oncology platform showing early promise
However, narsoplimab's BLA resubmission timeline remains uncertain and FDA approval isn't guaranteed even with favorable efficacy analysis.
– Conference Call Today at 4:30 p.m. ET
-
Net loss for the third quarter of 2024 was
$32.2 million $0.56 $37.8 million $0.60 $125.5 million $2.15 $108.8 million $1.73 -
At September 30, 2024, we had
$123.2 million $48.7 million $18.4 million $21.2 million $1.9 million - In September, we held a presubmission meeting with FDA for our biologics license application (“BLA”) for narsoplimab, our lead antibody targeting MASP-2 and the lectin pathway of complement, in hematopoietic stem cell transplant-associated thrombotic microangiopathy (“TA-TMA”). The meeting was both collaborative and productive. As part of the meeting, we received additional minor feedback on our proposed statistical analysis plan for the primary endpoint – patient survival in our pivotal narsoplimab trial compared to that in an external registry of patients with TA-TMA. FDA had previously reviewed the plan and all comments had been incorporated. The additional feedback was limited to requesting a few additional sensitivity analyses. We accordingly revised and resubmitted our statistical analysis plan shortly thereafter and expect to receive FDA's reply imminently. Assuming general alignment on the revised plan, we intend to proceed with conducting the primary and secondary efficacy analyses after incorporating, as appropriate any additional agency feedback on the plan. If the results support resubmission, we intend to finalize and resubmit our BLA as soon as possible. We expect to provide a further update on our plans for resubmission and relevant timing after the efficacy analyses have been conducted.
- Preparations are also underway for the European marketing authorization application (“MAA”) for narsoplimab in TA-TMA, which we expect to submit in the first half of 2025.
- Zaltenibart (formerly known as OMS906), our lead MASP-3 antibody targeting the key activator of the alternative pathway of complement, continued to advance rapidly through its Phase 2 development program in paroxysmal nocturnal hemoglobinuria (“PNH”). In September and October 2024, we met with FDA and European regulators to discuss further details of our planned Phase 3 program for zaltenibart in PNH. With both regulatory agencies, we discussed data developed from our clinical and nonclinical programs to date as well as our plans for Phase 3 development of zaltenibart in PNH. Both regulatory agencies agreed with the design of our proposed studies as well as our dose-finding strategy and provided other valuable feedback to inform our development plans. We now have a clear path to opening Phase 3 enrollment, which we expect in early 2025.
- Sites for the zaltenibart Phase 2 trial in C3 glomerulopathy (“C3G”) are open to enrollment in multiple countries and dosing in the study is ongoing. We are targeting initiation of our Phase 3 program for C3G in the first half of 2025.
“We expect that our September presubmission meeting with FDA and the minor revisions requested and incorporated in our analysis plan should clear the way to resubmit our BLA for narsoplimab in TA-TMA,” said Gregory A. Demopulos, M.D., Omeros’ chairman and chief executive officer. “While driving toward BLA and MAA submissions and preparing for the market launch of narsoplimab, we have also made tremendous progress in our other clinical development programs. For zaltenibart – with strong and growing physician support – successful end-of-Phase-2 meetings with both FDA and European regulators together with the manufacturing of sufficient drug supply enable us to advance directly into Phase 3 PNH enrollment, planned for early 2025, with C3G Phase 3 initiation targeted to follow soon thereafter. As we identify an appropriate large-market indication, our long-acting MASP-2 inhibitor OMS1029 stands ready to begin Phase 2 clinical trials. In our OMS527 program targeting addictive and compulsive disorders, we anticipate starting next year our NIDA-funded trial in adult patients with cocaine-use disorder. In parallel, our preclinical oncology programs are rapidly generating exciting in vitro and in vivo data as we build our patent position. We look forward to sharing more about the progress and prospects of all these programs in the coming months.”
Third Quarter and Recent Clinical Developments
-
Recent developments regarding narsoplimab, our lead monoclonal antibody targeting mannan-binding lectin-associated serine protease-2 (“MASP-2”), the effector enzyme of the lectin pathway, include the following:
- We have been engaged in ongoing discussions with FDA regarding the anticipated resubmission of our BLA for narsoplimab in TA-TMA, as described above. We do not expect the need for any additional discussion following FDA’s pending reply to our September submission of the revised statistical analysis plan incorporating requested additional sensitivity analyses so, following receipt of FDA’s response, we intend to proceed with conducting the primary and secondary efficacy analyses after incorporating, as appropriate, any additional agency feedback on the plan. If the analysis results support resubmission, we intend to finalize and resubmit our BLA as soon as possible. Even if the results of the efficacy analysis are favorable and FDA accepts our resubmitted BLA for review, as with any BLA or new drug application (“NDA”), there can be no guarantee that FDA will approve narsoplimab for TA-TMA. We expect to provide a further update on our plans for resubmission and relevant timing after the efficacy analyses have been performed.
- Preparations are also underway for the European MAA for narsoplimab in TA-TMA, which we expect to submit in the first half of 2025.
- Two manuscripts are in preparation by panels of leading international transplant experts - the first will compare survival in patients in the narsoplimab pivotal trial to survival in the same rigorous external control population of TA-TMA patients to be used in our BLA primary analysis and the second detailing the survival data of nearly 140 adult and pediatric TA-TMA patients treated with narsoplimab under our expanded access program. Physicians continue to request access to narsoplimab under this program for their patients with TA-TMA, many who have failed off-label treatment with one or more other complement inhibitors and/or defibrotide.
- We are continuing our work exploring the potential of narsoplimab and MASP-2 inhibition in severe acute and long COVID (also known as post-acute sequelae of COVID-19, or PASC) as well as acute respiratory distress syndrome, or ARDS, including ARDS associated with H1N1 and H5N1 infection. We are also advancing a MASP-2/C1inh proprietary diagnostic assay for lectin pathway hyperactivation for use in severe acute and long COVID-19, ARDS, and other diseases and disorders.
-
Recent developments regarding OMS1029, our long-acting, next-generation MASP-2 inhibitor, include the following:
- Single- and multiple-ascending-dose Phase 1 studies of OMS1029 have now been completed and OMS1029 has been well tolerated to date with no safety concerns identified. Results of these studies, confirmed by pharmacokinetic and pharmacodynamic modeling and dose simulation, confirm once-quarterly, low-volume dosing either intravenously or subcutaneously.
- OMS1029 drug product has been manufactured and stored for future clinical trials and we continue to evaluate large-market indications in which to pursue Phase 2 clinical development of OMS1029, dependent on the availability of resources. Data from a primate study in one of these indications are pending.
-
Recent developments regarding zaltenibart, our lead monoclonal antibody targeting mannan-binding lectin-associated serine protease-3 (“MASP-3”), the key activator of the alternative pathway, include the following:
-
Results from the zaltenibart monotherapy stage of our Phase 2 “switch-over” trial evaluating two doses of zaltenibart in PNH patients who have had an unsatisfactory response to the C5 inhibitor ravulizumab will be presented in December at the Annual Meeting of the American Society of Hematology (“ASH”). The study, now completed, enrolled PNH patients receiving ravulizumab with zaltenibart added to provide combination therapy for 24 weeks. Those patients demonstrating a hemoglobin response with the combination therapy were then switched to zaltenibart monotherapy. Interim analysis results from the combination therapy stage of the trial were presented at the annual meeting of the European Hematology Association in June by Dr. Morag Griffin, an internationally recognized PNH expert from St. James University Hospital in
England . Dr. Griffin will also give the ASH presentation showing that zaltenibart monotherapy resulted in sustained and clinically meaningful improvements in hemoglobin levels and absolute reticulocyte counts while preventing both extravascular and intravascular hemolysis. - In addition to our end-of-phase-2 meetings with FDA and European regulators as described above, in preparation for potential commercialization of zaltenibart, we also held a successful engagement with the German Federal Joint Committee, or G-BA – the decision-making body in the German healthcare system that specifies which medical treatments are reimbursed by the statutory health insurance funds. The GB-A provided us with productive feedback on the patient-reported-outcome measures, helpful in securing more attractive pricing, that we plan to incorporate in our Phase 3 program for zaltenibart in PNH.
- In October 2024, we announced that zaltenibart received rare pediatric disease designation from FDA for the treatment of C3G. Companies awarded a rare pediatric disease designation are eligible to receive a rare pediatric disease priority review voucher from FDA when the designated drug’s first approval is for the associated indication in the pediatric population. The holder of a priority review voucher is entitled to obtain priority review by FDA of either a BLA or an NDA for a different product and/or indication, reducing the review time and accelerating any granted approval and subsequent market entry by at least four months. The voucher may be used by the original recipient, or it can be sold for use by another company.
-
Results from the zaltenibart monotherapy stage of our Phase 2 “switch-over” trial evaluating two doses of zaltenibart in PNH patients who have had an unsatisfactory response to the C5 inhibitor ravulizumab will be presented in December at the Annual Meeting of the American Society of Hematology (“ASH”). The study, now completed, enrolled PNH patients receiving ravulizumab with zaltenibart added to provide combination therapy for 24 weeks. Those patients demonstrating a hemoglobin response with the combination therapy were then switched to zaltenibart monotherapy. Interim analysis results from the combination therapy stage of the trial were presented at the annual meeting of the European Hematology Association in June by Dr. Morag Griffin, an internationally recognized PNH expert from St. James University Hospital in
-
Recent developments regarding OMS527, our phosphodiesterase 7 (“PDE7”) inhibitor program focused on addictions and compulsive disorders as well as movement disorders, include:
-
Our lead orally administered PDE7 inhibitor compound is being developed for the treatment of cocaine use disorder (“CUD”) with funding from a three-year,
$6.69 million - As previously disclosed, we are exploring the potential use of OMS527 in movement disorders, specifically levodopa-induced dyskinesias, or LID.
-
Our lead orally administered PDE7 inhibitor compound is being developed for the treatment of cocaine use disorder (“CUD”) with funding from a three-year,
-
Recent developments regarding our oncology platform comprising signaling-driven immunomodulators, oncotoxins, and an adoptive T-cell technology combined with an immunostimulator, include:
- In vitro and in vivo studies are rapidly advancing and support the potential of our oncology platform to deliver broadly effective and safe cancer treatments for both hematological and solid tumors to overcome the shortcomings of currently marketed therapies while expanding our intellectual property estate.
-
We have begun raising the visibility of our “stealth” oncology programs, starting at the annual meeting of the Society of Immunotherapy of Cancer in
Houston earlier this week and at the upcoming ASH meeting inSan Diego . We plan to share further information on these programs publicly in the coming months.
Financial Results
Net loss for the third quarter of 2024 was
At September 30, 2024, we had
For the third quarter of 2024, we earned OMIDRIA royalties of
Total operating expenses for the third quarter of 2024 were
Interest expense during the third quarter of 2024 was
During the third quarter of 2024, we earned
Net income from discontinued operations, net of tax, was
Conference Call Details
Omeros’ management will host a conference call and webcast to discuss the financial results and to provide an update on business activities. The call will be held today at 1:30 p.m. Pacific Time; 4:30 p.m. Eastern Time.
For online access to the live webcast of the conference call, go to Omeros’ website at https://investor.omeros.com/upcoming-events.
To access the live conference call via phone, participants must register at the following URL https://register.vevent.com/register/BIf3c1eb9c93ae411eac97126f51f6c200 to receive a unique PIN. Once registered, you will have two options: (1) Dial in to the conference line provided at the registration site using the PIN provided to you, or (2) choose the “Call Me” option, which will instantly dial the phone number you provide. Should you lose your PIN or registration confirmation email, simply re-register to receive a new PIN.
A replay of the call will be made accessible online at https://investor.omeros.com/archived-events.
About Omeros Corporation
Omeros is an innovative biopharmaceutical company committed to discovering, developing and commercializing first-in-class small-molecule and protein therapeutics for large-market and orphan indications targeting immunologic disorders, including complement-mediated diseases and cancers, as well as addictive and compulsive disorders. Omeros’ lead MASP-2 inhibitor narsoplimab targets the lectin pathway of complement and is the subject of a biologics license application pending before FDA for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy. Omeros’ long-acting MASP-2 inhibitor OMS1029 has successfully completed Phase 1 single- and multiple-ascending dose clinical studies. OMS906, Omeros’ inhibitor of MASP-3, the key activator of the alternative pathway of complement, is advancing toward Phase 3 clinical trials for paroxysmal nocturnal hemoglobinuria and complement 3 glomerulopathy. Funded by the National Institute on Drug Abuse, Omeros’ lead phosphodiesterase 7 inhibitor OMS527 is in clinical development for the treatment of cocaine use disorder. Omeros also is advancing a broad portfolio of five novel cellular and molecular immuno-oncology programs. For more information about Omeros and its programs, visit www.omeros.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, which are subject to the “safe harbor” created by those sections for such statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “goal,” “intend,” “likely,” “look forward to,” “may,” “objective,” “plan,” “potential,” “predict,” “project,” “should,” “slate,” “target,” “will,” “would” and similar expressions and variations thereof. Forward-looking statements, including statements regarding the anticipated next steps in relation to the biologics license application for narsoplimab, the timing of regulatory events, the availability of clinical trial data, the prospects for obtaining FDA approval of narsoplimab in any indication, expectations regarding the initiation or continuation of clinical trials evaluating Omeros’ drug candidates and the anticipated availability of data therefrom, expectations regarding future cash expenditures, and expectations regarding the sufficiency and availability of our capital resources to fund current and planned operations, are based on management’s beliefs and assumptions and on information available to management only as of the date of this press release. Omeros’ actual results could differ materially from those anticipated in these forward-looking statements for many reasons, including, without limitation, unanticipated or unexpected outcomes of regulatory processes in relevant jurisdictions, unproven preclinical and clinical development activities, our financial condition and results of operations, regulatory processes and oversight, challenges associated with manufacture or supply of our products to support clinical trials, regulatory process and/or commercial sale following any marketing approval, changes in reimbursement and payment policies by government and commercial payers or the application of such policies, failure by Congress to reauthorize the priority review voucher program or other legislative developments, intellectual property claims, competitive developments, litigation, and the risks, uncertainties and other factors described under the heading “Risk Factors” in our Annual Report on Form 10-K filed with the Securities and Exchange Commission on April 1, 2024, an in our subsequently filed quarterly reports on Form 10-Q. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and we assume no obligation to update these forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.
OMEROS CORPORATION UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (In thousands, except share and per share data) |
||||||||||||||||
|
|
|
|
|
|
|
||||||||||
|
|
Three Months Ended |
|
|
Nine Months Ended |
|
||||||||||
|
|
September 30, |
|
|
September 30, |
|
||||||||||
|
|
2024 |
|
|
2023 |
|
|
2024 |
|
|
2023 |
|
||||
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Costs and expenses: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||
Research and development |
|
$ |
24,084 |
|
|
$ |
31,731 |
|
|
$ |
96,203 |
|
|
$ |
85,980 |
|
Selling, general and administrative |
|
|
11,323 |
|
|
|
16,422 |
|
|
|
37,395 |
|
|
|
38,785 |
|
Total costs and expenses |
|
|
35,407 |
|
|
|
48,153 |
|
|
|
133,598 |
|
|
|
124,765 |
|
Loss from operations |
|
|
(35,407 |
) |
|
|
(48,153 |
) |
|
|
(133,598 |
) |
|
|
(124,765 |
) |
Interest expense |
|
|
(4,052 |
) |
|
|
(7,916 |
) |
|
|
(21,498 |
) |
|
|
(23,781 |
) |
Interest and other income |
|
|
2,346 |
|
|
|
4,413 |
|
|
|
9,008 |
|
|
|
12,913 |
|
Net loss from continuing operations |
|
|
(37,113 |
) |
|
|
(51,656 |
) |
|
|
(146,088 |
) |
|
|
(135,633 |
) |
Net income from discontinued operations, net of tax |
|
|
4,881 |
|
|
|
13,906 |
|
|
|
20,631 |
|
|
|
26,888 |
|
Net loss |
|
$ |
(32,232 |
) |
|
$ |
(37,750 |
) |
|
$ |
(125,457 |
) |
|
$ |
(108,745 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Basic and diluted net income (loss) per share: |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Net loss from continuing operations |
|
$ |
(0.64 |
) |
|
$ |
(0.82 |
) |
|
$ |
(2.51 |
) |
|
$ |
(2.16 |
) |
Net income from discontinued operations |
|
|
0.08 |
|
|
|
0.22 |
|
|
|
0.36 |
|
|
|
0.43 |
|
Net loss |
|
$ |
(0.56 |
) |
|
$ |
(0.60 |
) |
|
$ |
(2.15 |
) |
|
$ |
(1.73 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Weighted-average shares used to compute basic and diluted net income (loss) per share |
|
|
57,948,093 |
|
|
|
62,856,721 |
|
|
|
58,232,007 |
|
|
|
62,840,990 |
|
OMEROS CORPORATION UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEET (In thousands) |
||||||||
|
|
|
|
|
||||
|
|
September 30, |
|
December 31, |
||||
|
|
2024 |
|
2023 |
||||
Assets |
|
|
|
|
||||
Current assets: |
|
|
|
|
||||
Cash and cash equivalents |
|
$ |
1,521 |
|
|
$ |
7,105 |
|
Short-term investments |
|
|
121,636 |
|
|
|
164,743 |
|
OMIDRIA contract royalty asset, short-term |
|
|
29,243 |
|
|
|
29,373 |
|
Receivables |
|
|
6,394 |
|
|
|
8,096 |
|
Prepaid expense and other assets |
|
|
6,127 |
|
|
|
8,581 |
|
Total current assets |
|
|
164,921 |
|
|
|
217,898 |
|
OMIDRIA contract royalty asset |
|
|
129,488 |
|
|
|
138,736 |
|
Right of use assets |
|
|
15,933 |
|
|
|
18,631 |
|
Property and equipment, net |
|
|
1,939 |
|
|
|
1,950 |
|
Restricted investments |
|
|
1,054 |
|
|
|
1,054 |
|
Total assets |
|
$ |
313,335 |
|
|
$ |
378,269 |
|
|
|
|
|
|
||||
Liabilities and shareholders’ equity (deficit) |
|
|
|
|
|
|
||
Current liabilities: |
|
|
|
|
|
|
||
Accounts payable |
|
$ |
7,723 |
|
|
$ |
7,712 |
|
Accrued expenses |
|
|
23,246 |
|
|
|
31,868 |
|
OMIDRIA royalty obligation, current |
|
|
18,884 |
|
|
|
8,576 |
|
Lease liabilities, current |
|
|
5,770 |
|
|
|
5,160 |
|
Total current liabilities |
|
|
55,623 |
|
|
|
53,316 |
|
Convertible senior notes, net |
|
|
97,032 |
|
|
|
213,155 |
|
Long-term debt, net |
|
|
92,427 |
|
|
|
— |
|
OMIDRIA royalty obligation, non-current |
|
|
205,089 |
|
|
|
116,550 |
|
Lease liabilities, non-current |
|
|
14,242 |
|
|
|
18,143 |
|
Other accrued liabilities, non-current |
|
|
3,094 |
|
|
|
2,088 |
|
Shareholders’ equity (deficit): |
|
|
|
|
|
|
||
Common stock and additional paid-in capital |
|
|
724,815 |
|
|
|
728,547 |
|
Accumulated deficit |
|
|
(878,987 |
) |
|
|
(753,530 |
) |
Total shareholders’ deficit |
|
|
(154,172 |
) |
|
|
(24,983 |
) |
Total liabilities and shareholders’ equity (deficit) |
|
$ |
313,335 |
|
|
$ |
378,269 |
|
View source version on businesswire.com: https://www.businesswire.com/news/home/20241113240875/en/
Jennifer Cook Williams
Cook Williams Communications, Inc.
Investor and Media Relations
IR@omeros.com
Source: Omeros Corporation
FAQ
What was Omeros (OMER) Q3 2024 net loss?
How much cash does Omeros (OMER) have as of Q3 2024?
When does Omeros (OMER) expect to begin Phase 3 enrollment for zaltenibart in PNH?
What were Omeros (OMER) OMIDRIA royalties in Q3 2024?
